Lupin’s Nagpur Unit-1 Passes U.S. FDA Pre-Approval Inspection with Flawless Record

Lupin Limited, a leading global pharmaceutical company, has successfully completed a product-specific Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (U.S. FDA) at its major manufacturing facility in Nagpur, India.

Inspection Details and Outcome

Facility: Lupin’s Unit-1 oral solid dosage facility in Nagpur.
Duration: Four days, conducted from November 10 to November 14, 2025.
Inspection Type: Product-specific Pre-Approval Inspection (PAI). This type of inspection is conducted before the FDA grants final approval for a new drug application to ensure the facility is capable of manufacturing the product according to US standards.
Result: The inspection concluded with zero Form 483 observations.

Significance of Zero Form 483 Observations

A Form 483 is issued by FDA investigators when they observe any conditions or practices that may violate the U.S. Food, Drug, and Cosmetic Act or related regulations.

Zero Observations: This result is the highest level of compliance and indicates that the facility meets the U.S. FDA’s stringent standards for quality, manufacturing practices (cGMP), and safety with respect to the inspected products.
Market Impact: The successful PAI, particularly for a key oral solid dosage site like Nagpur Unit-1, significantly strengthens Lupin’s regulatory standing in the critical US market. It paves the way for potential near-term approval and commercial launch of the new products inspected.

Company Statement

Lupin’s Managing Director, Nilesh Gupta, expressed pride in the achievement:

“The successful outcome… exemplifies our commitment to uphold and maintain the highest standards of quality, compliance, and safety across our facilities. We remain dedicated to improving the lives of our patients globally.”

This milestone reinforces Lupin’s reputation as a reliable manufacturer and is expected to contribute positively to the company’s future growth in global markets.